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a  b  s  t  r  a  c  t
Over  60%  of people  aged  over  65 are  affected  by  multiple  morbidities,  which  are  more  difﬁcult  to  treat,
generate  increased  healthcare  costs  and  lead to poor  quality  of  life  compared  to  individual  diseases.  With
the number  of  older  people  steadily  increasing  this  presents  a societal  challenge.  Age  is the  major  risk
factor  for age-related  diseases  and  recent  research  developments  have  led to the  proposal  that  phar-
macological  interventions  targeting  common  mechanisms  of  ageing  may  be able to delay  the  onset  ofeywords:
ultimorbidity
geing
hronic diseases
eroprotectors
multimorbidity.  Here  we  review  the  state  of  the  knowledge  of  multimorbidity,  appraise  the  available  evi-
dence supporting  the  role  of  mechanisms  of  ageing  in  the  development  of  the  most  common  age-related
diseases  and  assess  potential  molecules  that may  successfully  target  those  key  mechanisms.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).eroscience
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. Introduction
The number of people over the age of 65 is predicted to double
n the next 50 years with consequent increase in the incidence of
ge-related chronic diseases such as arthritis, type 2 diabetes, can-
er, osteoporosis, cardiovascular and neurodegenerative disorders
http://europa.eu/epc/pdf/ageing report 2015 en.pdf). As a result
he costs in long term care are set to sharply increase (http://europa.
u/epc/pdf/ageing report 2015 en.pdf). Up until now, research has
ocused predominantly on single diseases often with a focus on
ortality as the main endpoint. However, this approach may no
onger serve patients and society well (Tinetti et al., 2012; Smith
t al., 2012). Approximately 60% of people over 65 s have been
hown to have multimorbidity (Vogeli et al., 2007) i.e. the pres-
nce of more than 1 condition at the same time, and this is the main
actor responsible for decreased quality of life and increased health-
are costs (Fortin et al., 2007; Fortin et al., 2004; Wolff et al., 2002).
n addition, there is evidence that treatments, which are effective
hen patients present only one disease, become far less so in the
resence of multimorbidity and there is an increasing risk of seri-
us side effects associated with polypharmacy (Marengoni et al.,
014; Tinetti et al., 2004). Recently studies commissioned by the
opulation level commissioning for the future in the UK were set
p to assess the burden of multimorbidity and ways to improve
linical outcomes (http://www.nhsiq.nhs.uk/news-events/news/
opulation-level-commissioning-for-the-future.aspx). In agree-
ent with other healthcare providers worldwide, the outcome was
he urgent need to identify interventions which are holistic and
ove away from the single disease model (Tinetti et al., 2012).
In an attempt to fulﬁl this need, a new paradigm has been pro-
osed to devise interventions, which target common mechanisms
f ageing to delay the onset of more than one age-related disease
t the same time and focus not on mortality as endpoint per se but
ather on contraction of the period of morbidity before death, or
n other words, healthspan (Riera and Dillin, 2015). In this review
e aim to give a brief overview of the available evidences that this
ay  be a sound approach. We  will consider the understanding of
ultimorbidity in terms of clustering, predictive risks and common
echanisms of ageing and discuss priority areas for the discovery
f new targets.
. Multimorbidity
At present it is unknown whether multimorbidity is the result
f random chance, common risk factors, common mechanisms or
he result of side effects of particular treatments. Deﬁning the eti-
logy of multimorbidity is particularly important in the decision of
hat mechanisms to target and for which group of diseases. What
s clear is that the prevalence of multimorbidity increases dramati- . . .  . .  . . . . .  . . . .  . . . .  . . .  . . .  . . .  .  .  . . .  . . . .  .  . . . . . . .  . . . . .  .  . . .  . . . . . .  .  . .  .  .  .  .  . . . .  . . .  . . . 84
cally with age and ageing is by far the strongest risk factor for many
chronic diseases (Barnett et al., 2012; Fabbri et al., 2015a). More-
over, patients with one disease have a higher risk of developing
multimorbidity than older individuals with no disease (Melis et al.,
2014). Fabbri et al., (2015c) proposed that ageing brings a dysreg-
ulation of multiple organ systems and when a certain threshold of
impairment is reached this is manifested in the onset of diseases
and their accumulation. They suggest that the onset of multimor-
bidity is a landmark for loss of resilience and homeostasis. If this
is the case, in order to implement strategies that slow the progres-
sion of ageing and the burden of multimorbidity it is necessary to
identify markers or risk factors which predict the onset of multi-
morbidity clusters (Fig. 1).
However, such approaches are still in their infancy. Attempts
to identify patterns of associated multimorbidity, where a group
of diseases occur together with a higher frequency than by chance
alone, have yielded inconsistent results due to the absence of stan-
dardization (van den Akker et al., 1998; Prados-Torres et al., 2014;
Marengoni et al., 2009; Schäfer et al., 2010). In particular, the lack of
a deﬁnition of what constitutes multimorbidity, in particular how
many conditions and which ones should be included in the deﬁni-
tion, has made it difﬁcult to compare ﬁndings across studies and
reach conclusion even on simple parameters such as incidence (Le
Reste et al., 2015; Fortin et al., 2012).
In an attempt to identify risk factors that predict the onset of
multimorbidity the InCHIANTI study and the Baltimore longitudi-
nal study of ageing have found that age-related proinﬂammatory
state such as elevated level of Interleukin-6 (IL-6), Tumor Necrosis
factor alpha receptor 2 (TNFAR2), Interleukin-1 Receptor Antag-
onist (IL-1RA) and decline in dehidroepiandrosterones (DHEAS)
were found to be associated with higher multimorbidity, rela-
tive to participants with normal level of the same markers. In
addition higher baseline IL-6 and steeper increase of IL-6 were asso-
ciated with increasing number of chronic diseases (Fabbri et al.,
2015a,b). Although encouraging, there is a pressing need for more
studies such as these in order to identify risks which are predic-
tive in individual patients rather than simply at the population
level.
As there are no speciﬁc clusters of diseases that have been shown
to be tightly associated in age-related morbidity, we  have consid-
ered the most prevalent diseases in the ageing population. We  focus
on cardiovascular (atherosclerosis), musculoskeletal (osteoporosis
and osteoarthritis), metabolic (Type 2 diabetes) and neurodegen-
erative (Alzheimer’s and Parkinson disease) disorders and review
the evidence for ageing mechanisms and key nodes common to all
these diseases. We  ﬁnd evidence that processes related to inﬂam-
mation, autophagy, DNA damage and senescence are consistently
altered across all these disorders.
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Fig. 1. Schematic representation of the proposed sequence of events moving from age-related alterations to multimorbidity. The multi-system loss of reserve and function
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. Mechanisms of ageing
.1. Inﬂammation and senescence
Inﬂammageing has been described as a chronic state of low-
rade, inﬂammation that ensues with ageing (Franceschi and
ampisi, 2014). This persistent, non-resolved inﬂammation con-
ributes to tissue damage, which contrasts with the acute, transient,
atural response to pathogens that is required for the mainte-
ance of tissue homeostasis. There are multiple potential sources
f inﬂammageing, which are all potentiated by the concomi-
ant impairment of the immune system with ageing, termed
immunosenescence” (Frasca and Blomberg, 2015; Campos et al.,
014; Linton and Thoman, 2014; Macaulay et al., 2013). Immunose-
escence is associated with an increased susceptibility to infectious
isease, cancer and decreased response to vaccination (Chebel et al.,
009; Clambey et al., 2005; Plunkett et al., 2005, 2007; Reed et al.,
004; Weng, 2008), and is mainly thought to be a consequence
f repeated antigen exposure throughout life (Akbar and Henson,
011; Franceschi et al., 2007). Immunosenescence affects both the
nnate and the adaptive immune system (Frasca and Blomberg,
015; Akbar and Henson, 2011).bility to chronic diseases. This phenomenon manifests clinically as multimorbidity
intervention is between multi-system loss of reserve and single morbidity (adapted
This repeated mild, chronic activation of the immune system
leads to a chronic secretion of inﬂammatory factors, which is ulti-
mately a hallmark of inﬂammageing itself. For example, chronic
exposure to viruses such as cytomegalovirus (CMV), namely
B-herpes virus HHV5, as well as endogenous, host-derived dam-
aged macromolecules, reactive oxidative species (ROS) and cell
debris lead to re-current activation and re-modelling of inﬂam-
matory networks (Franceschi and Campisi, 2014; Freeman, 2009;
Pawelec et al., 2010; Salminen et al., 2012). The inﬂammatory
networks have been shown to be mediated in vitro by activation
of NF-B-mediated signalling networks, including transcription of
proinﬂammatory TNF- (Prosch et al., 1995). Interestingly, NF-B
signalling has both positive and negative effects as it is also required
as host defence mechanisms against CMV  replication (Eickhoff and
Cotten, 2005). Another source of inﬂammageing comes from micro-
bial components that reside in oral and gut cavities, which due
to immunosenescence and compromised integrity of the intestinal
barrier (Mabbott et al., 2015; Saffrey, 2014) leak into other tissues
and activate inﬂammatory networks, which will differ depend-
ing on the pathogen. Furthermore, the microbiome itself has been
shown to change dramatically with ageing, which may  also con-
tribute to inﬂammation (Biagi et al., 2010; Rampelli et al., 2013).
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Over-time persistent sources of low-grade inﬂammation are
hought to lead to immune dysfunction, as both innate and adap-
ive ageing immune cells become incompetent in responding to
cute stimuli, including viral infections and decreased antibody
roduction in response to vaccination (McElhaney et al., 2012).
herefore, even though there is a chronic activation of the immune
nd inﬂammatory networks in the elderly, acute inﬂammatory
esponses and consequent immune protection are reduced (Frasca
nd Blomberg, 2015). The balance between pro-inﬂammatory and
nti-inﬂammatory cytokines is shifted during ageing. In particular,
nﬂammageing is characterised by an increase in proinﬂammatory
ytokines in the blood of aged people, namely IL-6 (Wikby et al.,
006; Giacconi et al., 2004), IL-8 (Zanni et al., 2003), IL-15 (Zanni
t al., 2003) and TNF- (Bruunsgaard et al., 1999) and other inﬂam-
atory markers such as C-reactive protein (CRP), combined with
ecreased anti-inﬂammatory cytokines such as IL-10 (Frasca and
lomberg, 2015; Franceschi et al., 2007).
In addition, several lines of evidence now point to the accu-
ulation of senescent cells in aged tissues as a signiﬁcant factor
ontributing to inﬂammageing (Freund et al., 2010). Cellular senes-
ence is a distinct state, initially identiﬁed by Hayﬂick in the
960’s (Hayﬂick, 1965), by showing that in vitro cultivated human
broblasts reached a replicative limit after approximately 50 cell
opulation doublings- termed “Hayﬂick’s limit”. This replicative
imit is caused by telomere shortening and eventual cellular dys-
unction, since human cells lose about 100 bp of telomere sequence
er cell doubling, in the absence of compensatory mechanisms
uch as activation of the enzyme telomerase (Bodnar et al., 1998;
arlseder et al., 2002). Critically short and dysfunctional telom-
res cause cells to stop dividing, resulting in either apoptosis or
n irreversible state of “dormancy” termed replicative, telomere-
ependent senescence. However, cellular senescence can also
e induced by telomere-independent mechanisms, such as by
ncogene-induced reactive oxidative stress (Chandeck and Mooi,
010), mitochondria dysfunction (Correia-Melo and Passos, 2015)
r through exogenous factors such as exposure to ionising radia-
ion, as is the case for radiotherapy treatments in cancer (Mirzayans
t al., 2013). Senescent cells do not divide, which means they
an no longer take part in the proliferative requirements of the
issue, but they are metabolically active. Such cells secrete sev-
ral tissue remodelling factors including matrix metalloproteinases
MMPs), proinﬂammatory cytokines and chemokines, termed the
enescence-Associated Secretory Phenotype (SASP) (Coppe et al.,
010).
In young, healthy tissues, senescent cells play a normal role
n wound healing, by recruiting tissue-resident immune cells that
ontribute to tissue healing and clearance of senescent and apop-
otic cells (Adams, 2009; Sagiv and Krizhanovsky, 2013). In ageing,
owever, this balance is somehow tipped, and senescent cells
ccumulate in tissues of different organisms including zebraﬁsh
Henriques et al., 2013; Kishi, 2004), mice (Krishnamurthy et al.,
004), primates (Jeyapalan et al., 2007) and humans (Dimri et al.,
995). This means that aberrant accumulation of senescent cells
egatively impacts on tissue repair in both a cell autonomous,
y impaired proliferation, and in a non-cell-autonomous man-
er via SASP positively re-enforcing inﬂammageing (Ohtani and
ara, 2013). Moreover, adding to the complexity of this non-cell
utonomous positively re-enforcing network, recent data shows
hat senescent cells can induce senescence in adjacent cells in a
aracrine manner (Acosta et al., 2013). In particular, chronic inﬂam-
ation caused by NF-B activation has been shown to lead to
elomere dysfunction and ageing phenotypes that were underlined
y an accumulation of senescence (Bernal et al., 2014; Jurk et al.,
014).
All factors contributing to inﬂammageing are further modulated
y the individual’s genetic background, where different single-nd Development 160 (2016) 69–92
nucleotide polymorphisms (SNPs) in both the promoter of the
proinﬂammatory cytokine IL-6 (Giacconi et al., 2004; Fishman
et al., 1998; Olivieri et al., 2002) and IFN-γ (Lio et al., 2002a) as
well as anti-inﬂammatory IL-10 (Lio et al., 2002b), regulate the
individual’s susceptibility to inﬂammageing and morbidity. More
importantly inhibition of NF-B as well selective removal of senes-
cence in premature ageing mouse models that suffer from chronic
inﬂammation (Osorio et al., 2012) or accumulation of senescence,
respectively (Baker et al., 2016), can signiﬁcantly reduce ageing
phenotypes and improve health span (Baker et al., 2011), suggest-
ing a causal relationship between inﬂammation and ageing.
3.2. Oxidative stress
DNA damage (or genomic instability) is accumulated in our
tissues during ageing, contributing to loss of functionality and
regenerative capacity. During DNA replication errors may  occur as
a result of misincorporation of nucleotides opposite modiﬁed DNA
bases or by incorporation of modiﬁed nucleotides. Furthermore,
DNA is constantly exposed to damaging agents from both endoge-
nous and exogenous sources. If these lesions are not repaired they
can lead to mutations and result in cellular dysfunction including
uncontrolled cell proliferation, apoptosis or senescence. Thus, in
order to maintain the integrity of the genome, a complicated inte-
grated system of DNA repair pathways remove the vast majority of
the excess of deleterious lesions (Harper and Elledge, 2007; White
RyanÂ and Vijg, 2016; Hoeijmakers, 2009). However, DNA repair
may  occasionally fail or become limited due to an excess of DNA
damage resulting in DNA damage accumulation. In such situations
DNA damage is pathogenic and one of the most serious sequelae of
DNA repair deﬁciency is carcinogenesis.
Aerobic cellular metabolism is the primary source of endoge-
nous reactive oxygen species (ROS). Pathways and events that
produce ROS include mitochondrial and peroxisomal metabolism,
enzymatic synthesis of nitric oxide (NO), phagocytic leukocytes,
heat, ultraviolet (UV) light, therapeutic drugs, oxidizing agents,
ionizing radiation, and redox-cycling compounds. The reaction of
ROS with pyrimidines and purines produce a variety of different
DNA lesions (Cooke et al., 2003). Superoxide radicals are normally
dismutated by superoxide dismutase (SOD), to form the less reac-
tive hydrogen peroxide (H2O2) and O2. H2O2 is further converted
to H2O and O2 by catalase. SOD is present within mitochondria
(SOD2, Mn-SOD), cytoplasm (SOD1, CuZn-SOD) and extracellularly
(SOD3, EC-SOD) (Zelko et al., 2002). A large number of other factors
also contribute to cellular defence against ROS, for example argi-
nine, vitamins A, C, and E, thiols (glutathione), polyphenols (tea),
enzyme-bound minerals (selenium and zinc), and enzymes such as
glutathione reductase and glutathione peroxidases. All these are
important for preventing damage of amino acids, proteins, and
lipids (Fang et al., 2002).
Mitochondrial respiration is the major source of endogenous
ROS. Under normal physiological conditions electrons leak from
the electron transport chain converting about 1–2% of oxygen
molecules into O2− (Boveris and Cadenas, 1975; Boveris, 1977;
Loft and Poulsen, 1996; Papa, 1996). Mitochondrial dysfunction can
lead to increased ROS production (Bai et al., 1999; Esposito et al.,
1999; Raha and Robinson, 2000) and the correct mitochondrial
function is important for to avoid accumulation of DNA mutation
in the mitochondrial DNA (Rasmussen et al., 2003; Karthikeyan
et al., 2002; Mandavilli et al., 2002). However, mitochondria are
not only involved in generation of oxidative damage they also have
an effect on repair of DNA lesions. It was shown that a human cell
line depleted of the mitochondrial genome showed impaired repair
of H2O2-induced DNA damage (Delsite et al., 2003). Pre-exposure
of human cells to H2O2 also suppresses DNA repair of alkylation
damage (Hu et al., 1995) suggesting that extensive oxidative dam-
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age groups (Woolf and Pﬂeger, 2003). Osteoarthritis, back pain
and osteoporosis are the 3 leading cause for medical consultationI. Figueira et al. / Mechanisms of Ag
ge inhibits cellular repair systems. One possible target could be
he mitochondrial DNA polymerase  since it was  shown that this
nzyme is a target of oxidative damage, which might result in
educed replication of the mitochondrial genome as well as attenu-
ted repair capacity (Graziewicz et al., 2002). Overall, these results
ndicate that optimal mitochondrial function is important for both
ptimal repair of oxidative DNA damage and prevention of oxida-
ive damage.
.3. Proteasome and lysosome
Proteins are continuously damaged by various intrinsic and
xtrinsic factors. Aggregation of damaged proteins depends on
he balance between their generation and their elimination
y protein degradation (Chondrogianni et al., 2014; Morimoto
nd Cuervo, 2014). This aggregation affects several intracellular
athways, results in the eventual failure of organism homeo-
tasis, which, in turn, associates with the appearance of several
egenerative diseases and ageing (López-Otín et al., 2013). The
biquitin-Proteasome-System (UPS) is responsible for the degra-
ation of normal as well as damaged proteins. Speciﬁcally, the 26S
roteasome consists of the catalytic 20S core and the 19S regula-
ory complex. Whereas the 20S complex confers the proteolytic
ctivities of the proteasome, the documented role of 19S is to
ecognize, unfold, de-ubiquitinate and control the entry of multi-
biquitinated substrates into the 20S proteasome (Finley, 2009;
eissman et al., 2011).
Many studies have shown a general decline of proteasome
ctivities in different aged tissues (Chondrogianni et al., 2015).
enescent human cells resulted in decreased levels of the -
atalytic subunits that, in turn, result in lower proteasome content
nd activities in these cells (Chondrogianni et al., 2003). These
n vitro ﬁndings are supported by in vivo evidence. Speciﬁ-
ally, Kasahara and colleagues have shown that transgenic mice
ngineered with decreased levels of chymotrypsin-like (CT-L) pro-
easome activity exhibit an accelerated age-related phenotype
Tomaru et al., 2012). In addition, proteasome activation obtained
y overexpressing the 5 subunit in different human cell lines
esulted in increased rates of proteolysis and cell survival follow-
ng treatment with various cytotoxic agents (Catalgol et al., 2009;
hondrogianni et al., 2005). Importantly, overexpression of the
5 subunit signiﬁcantly extended lifespan in human primary cul-
ures (Chondrogianni et al., 2005). Moreover, recent comparative
tudies have reported that longer lived species have greater pro-
easome levels in immune cells and enhanced proteostasis relative
o shorter-lived species (Pickering et al., 2015; Pride et al., 2015).
In contrast to the substrate degradation speciﬁcity of the
roteasome, lysosomal degradation has a nearly unlimited degra-
ation capacity. Autophagy is a lysosomal bulk degradation process
nvolved in the clearance of long-lived proteins and organelles.
he mechanism for the delivery of cargo to the lysosomes gives
ise to the different forms of autophagy, namely macroautophagy,
icroautophagy and chaperone-mediated autophagy (Guo et al.,
012; Mijaljica et al., 2011; Orenstein and Cuervo, 2010). Lev-
ls of autophagy are under the tight control of multiple signal
ransduction pathways that are highly altered by various envi-
onmental signals (Chen and Klionsky, 2011; Levine and Kroemer,
008). The best characterised regulator of autophagy is the (mam-
alian) target of rapamycin (mTOR (Jung et al., 2010, 2009)).
TOR is, in turn, regulated by various pathways. For instance,
pon binding of insulin (or growth factors) to the insulin recep-
or, tyrosine kinases activate insulin substrate receptors that lead
o subsequent AKT activation and stimulation of mTOR activity
Lionaki et al., 2013). Speciﬁcally, AKT promotes mTORC1 activity
hrough multiple phosphorylation of TSC2, an upstream negative
egulator of mTORC1, and in turn mTORC1 downstream kinasend Development 160 (2016) 69–92 73
S6K1 blocks PI3K via phosphorylation of IRS1 to complete the
negative feed-back loop. Another regulator is p53. Following acti-
vation by genotoxic or oncogenic stimuli, p53 transactivates several
autophagy inducers including DRAM1 (which operates through
JNK1 activation) and SESTRIN2 (which binds to the ternary complex
TSC1/TSC2-AMPK, inducing phosphorylation and activation of TSC2
by AMPK (Kroemer et al., 2010)). In this case, TSC2 is activated via
AMPK which means that mTORC1 signaling pathway is ultimately
involved. These intriguing data propose that there is a mechanis-
tic overlap between mTORC1 and p53 (Hay, 2008). Importantly,
genetic or chemical inhibition of p53 also activates autophagy
(Fleming et al., 2011). An additional level of autophagy control
occurs via the Beclin 1/VPS34 complex (Simonsen and Tooze, 2009;
Sinha and Levine, 2008). Notably the apoptosis-related proteins
BCL-2 or BCL-XL can bind Beclin 1 and inhibit autophagy (Lalaoui
et al., 2015). In contrast, serum levels of Beclin 1 are increased in
healthy centenarians (Emanuele et al., 2014).
Several studies suggest that the decline of lysosomal and
autophagic proteolytic activity during ageing correlates with the
accumulation of damaged proteins and organelles (Rajawat et al.,
2009; Rubinsztein et al., 2011). As a consequence, the loading
of lysosomes with lipofuscin during ageing, interferes with their
ability to fuse with autophagosomes and degrade their cargo
(Terman et al., 2007). Moreover a recent study highlights that
loss of chaperone-mediated autophagy accelerates proteostasis
failure during ageing (Schneider et al., 2015). Other work has
documented the reduced expression of essential components of
the autophagic machinery in different tissues during ageing and
age-related pathologies (Rubinsztein et al., 2011). For instance in
mice, the depletion of essential ATG proteins (key components
of autophagosomes) during the early postnatal period is lethal
(Levine and Kroemer, 2008). The age-associated phenotypes that
were observed in tissue-speciﬁc ATG deﬁcient mice (i.e. increased
levels of oxidized proteins, accumulation of age-pigments into
lysosomes, ubiquitin-containing aggregates and malfunctioning
mitochondria) highlight the important role of autophagy during
ageing (Komatsu et al., 2005; Nakai et al., 2007).
Autophagy is also required for lifespan extension induced by
activation of sirtuins (Morselli et al., 2010). Several autophagy
proteins, such as ATG5, ATG7, and ATG8 that are known to be
major regulators of autophagy, are deacetylated by SIRT1 in a
NAD-dependent manner, while overexpression of sirt1 induces
autophagy (Lee et al., 2008). Moreover, overexpression of ATG5
not only activates autophagy but also directly increases lifespan
in mice (Pyo et al., 2013). Conversely, knock-down or deﬁciency of
autophagy components reverses these effects, (Alvers et al., 2009;
Bjedov et al., 2010; Eisenberg et al., 2009; Morselli et al., 2009).
These data indicate that autophagy is a common downstream effec-
tor in various life-prolonging signalling pathways (Folick et al.,
2015).
4. Mechanisms of ageing and chronic age-related diseases
4.1. Musculoskeletal diseases
Musculoskeletal conditions cause more functional limitations
in the adult population in the western world than any other group
of disorders and are the main cause of disability among older(Woolf and Pﬂeger, 2003). Whilst there is little understanding of the
causes leading to back pain, intense research efforts are on-going
to understand the causes of osteoarthritis and osteoporosis.
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.1.1. Osteoarthritis (OA)
Increased age is the most important risk factor for the initiation
nd progression of osteoarthritis a condition which typically affects
he joints (Bijlsma et al., 2011). The articular cartilage is progres-
ively degraded leading to chronic pain and stiffness. Although the
efects in cartilage structure are the main feature of the disease,
ther joint structures are affected during OA including subchon-
ral bone, menisci, ligaments, synovial membrane and muscle
urrounding the affected joints (Bijlsma et al., 2011). Cartilage is
aintained by chondrocytes mainly through production of extra-
ellular matrix (Goldring, 2000). The onset of OA is characterised
y increased chondrocyte proliferation which leads to formation of
hondrocyte clusters and increased synthesis of irregular matrix
omponents such as proteoglycans and collagen (Rothwell and
entley, 1973). This is an attempt to repair the damaged extracellu-
ar matrix. With OA progression increased catabolic activity causes
xcessive cartilage breakdown. The catabolic events are largely
ediated by proinﬂammatory cytokines and mediators such as
etalloproteinases (Burrage et al., 2006). Current pharmacolog-
cal management of OA is limited to symptom’s alleviation and
here are no approved drugs which modify the course of the disease
Bijlsma et al., 2011). Therefore there is a great need to identify new
nterventions.
There is evidence that chondrocytes undergo several mecha-
isms of ageing including telomere shortening and senescence and
his inﬂuences their ability to produce extracellular matrix (Loeser,
009). However, most studies are on chondrocytes cultured in
itro in normoxia and under proliferative stress (Loeser, 2009).
t is known that in vivo chondrocytes rarely proliferate (Aigner
t al., 2001), and are exposed to low oxygen tension (Brighton
nd Heppenstall, 1971), consequently questioning how many of
he phenomenon described in vitro actually apply in vivo.
Focusing on the evidence that supports the presence of age-
ng mechanisms in vivo, the overproduction of ROS in the cartilage
f patients affected by OA has been well documented. Accumula-
ion of nitrotyrosine was observed in chondrocytes and degenerate
rticular cartilage compared to non-degenerate areas in the same
ample, suggesting that degenerated cartilage may  exhibit more
xidative damage than an intact region from the same OA carti-
age (Yudoh et al., 2005; Loeser et al., 2002). Moreover, decreased
xpression of ROS scavengers has also been described. In a study
n the expression of superoxide dismutase (SOD) family expres-
ion of all 3 forms of SOD were decreased at the transcriptional
evel in patients affected by OA (Scott et al., 2010). Immunoﬂuores-
ence studies revealed that mitochondrial superoxide dismutase
 (SOD2) was largely missing in OA but was present consistently
n the superﬁcial layer of normal cartilage (Ruiz-Romero et al.,
009). In addition the decreased expression of SOD2 was  related
o increased methylation of the SOD2 promoter suggesting an epi-
enetic regulation of its expression (Scott et al., 2010). In line
ith increased production of ROS and defects in the mitochondrial
ntioxidant system is the increased accumulation of mtDNA muta-
ions in the cartilage of patients affected by OA as compared to age
atched controls (Grishko et al., 2009).
Increased ROS is responsible for the presence of oxidative dam-
ge in DNA (Section 3.2.), which can directly contribute to apoptosis
r senescence. Whilst evidence of increased apoptosis and cell
eath in the cartilage of OA patients is controversial (Aigner et al.,
001; Sharif et al., 2004) evidence of senescence was  found in vivo
n terms of greater expression of p16-INK4A and -galactosidase in
A chondrocytes as compared to age-matched controls (Zhou et al.,
004; Price et al., 2002). Inhibition of p16-INK4A expression led to
ncreased ability of the cells to proliferate and increased matrix
ene expression when examined in vitro, suggesting a possiblend Development 160 (2016) 69–92
mechanism to explain the reduction in the ability of chondrocytes
to repair matrix in OA patients (Zhou et al., 2004).
It is well established that OA is associated with increased local
production of proinﬂammatory signals such as nitric oxide and
cytokines such as IL1, IL6 and TNF-alpha. These are overexpressed
in chondrocytes, stromal cells and synovial macrophages in OA
joint; these signals negatively affect the balance of cartilage matrix
degradation and repair (Goldring and Otero, 2011). It is unclear
how the proinﬂammatory process is initiated. Cytotoxic effects
and oxidative stress can both compromise chondrocyte viability
and activate inﬂammatory signals as demonstrated by the activa-
tion of NF-kB and mitogen activated protein kinases in surviving
chondrocytes (Goldring et al., 2011).
Mitochondrial dysfunction and inﬂammation have been linked
to decreased autophagy (Section 3.3). A decrease in autophagy
genes Beclin-1, ULK1 and LC3 was observed in the superﬁcial and
deep cartilage zone of patients with mild OA (Caramés et al., 2010).
In more advanced stages of OA these genes were downregulated in
all 3 zones (superﬁcial, middle and deep zone) compared to carti-
lage from age-matched controls (Caramés et al., 2010). In contrast
these genes were highly expressed in the middle zone and deep
zone in the early phase of OA when chondrocytes clusters were
formed as an attempt to repair cartilage (Caramés et al., 2010). This
was also reproduced in models of OA in mice (Caramés et al., 2010).
These data suggest that during the development of OA increased
autophagy may  reﬂect an adaptive response. When this response
fails, decreased autophagy may  lead to further degeneration. The
fact that autophagy decreases with age in human joint cartilage,
and precedes cartilage structural damage suggests that it may
play a role in the establishment of the disease. More importantly
decreased autophagy activity was shown to lead to OA-like changes
in the joint cartilage in ATG5 KO mice (Bouderlique et al., 2015).
Reduced autophagy leads to premature chondrocytes senescence,
increased matrix degradation and increase of metalloproteinases
and ROS (Bouderlique et al., 2015).
4.1.2. Osteoporosis
The adult skeleton is continuously remodelled by osteoclasts,
which resorb bone and osteoblasts, which form new bone. Imbal-
ance between bone formation and resorption leads to osteoporosis.
Increased age has long been associated with reduced bone mass,
which is largely thought to be due to hormonal deﬁciency, mainly
oestrogen due to menopause. However, age-associated bone loss
occurs even in individuals with normal levels of sex steroids (Riggs
et al., 2008). In addition, rodents do not experience a signiﬁcant
decline in sex steroids with age but bone mass declines and long
lived mice are resistant to age-related bone loss suggesting that
other mechanisms can contribute to reduced bone mass with age
(Almeida et al., 2007; Selman and Withers, 2011).
The RANKL/RANK signalling pathway is central to the process
of osteoclastogenesis and provides evidence of the interconnec-
tion between immune and skeletal systems. Osteoblasts and their
precursors express RANKL, which binds to the transmembrane
receptor RANK (receptor activator of nuclear factor -B) expressed
on the surface of osteoclasts and their precursors. It promotes
proliferation and differentiation of osteoclast precursors, and the
maturation and activity of osteoclasts. The osteoclastogenic activity
induced by RANKL-RANK binding is inhibited by another member
of the TNF receptor superfamily ‘osteoprotegerin’ (OPG) produced
by osteoblasts. Although RANKL and macrophage colony stimulat-
ing factor (M-CSF) are essential for osteoclastogenesis, additional
cytokines such as TNF-alpha and IL-1 are likely to contribute to
the regulation of osteoclast formation both in physiological and
pathological condition such as oestrogen deﬁciency and inﬂamma-
tion. This is based largely on animal studies of bone loss following
ovariectomy (Kimble et al., 1995; Lorenzo et al., 1998) and lim-
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ted evidence in postmenopausal women affected by osteoporosis.
ndeed epidemiologic studies report an increase in the risk of devel-
ping osteoporosis in various inﬂammatory conditions (Mitra et al.,
000; Haugeberg et al., 2004). Gene polymorphism in IL-1, IL-6 and
NF-alpha and their receptors has been shown to correlate with dif-
erent levels of bone mass in humans (Fontova et al., 2002; Tasker
t al., 2004; Chung et al., 2003). Similarly, IL-1 and IL-1 receptor
ntagonist (IL-1Ra) gene polymorphisms have been associated with
educed bone mineral density and osteoporosis at the lumbar spine
Chen et al., 2003) In addition mRNA for IL-1, IL-6 and TNF-alpha
as increased in a higher percentage of patients with fractures as
ompared with patients without fractures (Ralston, 1994). Anti-
NF drugs, currently used in the therapy of several immunological
isorders, are also useful in preventing and/or reversing systemic
one loss associated with the disease, targeting both the bone and
he inﬂammatory processes (Roux, 2011). The transcription fac-
or NF-B, activated in the presence of inﬂammation has a well
escribed role in osteoclastogenesis (Ruocco et al., 2005). More
ecently suppression of NF-B activity in differentiated osteoblasts
as shown to prevent bone loss in an ovariectomy mouse model by
aintaining osteoblast function (Chang et al., 2009). Although no
ata are currently available to conﬁrm that this mechanism is rel-
vant to patients affected by osteoporosis, the oestrogen receptor
as been found to directly inhibit NK-B transcription (Harnish,
006) and is expressed in osteoblasts suggesting that oestrogen
ay  regulate NF-B activities under physiological conditions.
The functional role of oxidative stress and autophagy in osteo-
orosis is still largely unexplored in patients and most of the data
erive from functional studies in mice. Suppression of autophagy
y deletion of ATG7 expression in osteocytes has been shown to be
ufﬁcient to mimic  many of the skeletal changes associated with
dvanced age in young adult mice (Onal et al., 2013). Although
t is unknown whether autophagy does indeed decline with age
n osteocytes or in cells at any stage of osteoblast differentiation,
he relationship between the autophagic pathway and osteoporosis
as highlighted in a genome wide association study of wrist bone
ineral density in human subjects (Zhang et al., 2010). This analysis
howed signiﬁcant association of wrist bone mineral density with
egulation of autophagy genes including ATG7 and Beclin1 (Zhang
t al., 2010).
An increased production of ROS, and associated decreases in
ntioxidants was demonstrated subsequent to the depletion of
estrogen in ovariectomised (OVX) mice (Almeida et al., 2007; Lean
t al., 2003). The levels of antioxidant enzymes superoxide dis-
utase, glutathione peroxidase and glutathione-s transferase were
ecreased in the femur of ovariectomized rats (Muthusami et al.,
005). The same enzymes were found to be lower in the plasma of
steoporotic patients (Maggio et al., 2003). In addition mice lacking
itochondrial SOD2 in osteocytes showed enhanced production
f cellular superoxide in vivo. A bone morphological analysis
emonstrated that the SOD1 and SOD2-deﬁcient femurs showed
emarkable bone loss in an age-dependent manner (Nojiri et al.,
011; Kobayashi et al., 2015). In particular, SOD2 deletion led to
isorganized osteocytic canalicular networks and decreased num-
er of live osteocytes (Kobayashi et al., 2015). Furthermore, SOD2
eﬁciency signiﬁcantly suppressed bone formation and increased
one resorption concomitant with the upregulation of sclerostin
nd RANKL (Kobayashi et al., 2015). Goettsch et al. (Goettsch
t al., 2013) found that intracellular NADPH oxidase 4 (NOX4),
n enzymatic source of ROS, was increased following ovariec-
omy in female mice, and NOX4 deletion reduced bone loss. More
mportantly in middle-aged women, NOX4 mutation was associ-
ted with altered parameters of bone metabolism, and conversely,
here was an increased expression of NOX4 in the bones of patientsnd Development 160 (2016) 69–92 75
with untreated osteoporosis as compared to age-matched controls
(Goettsch et al., 2013).
4.2. Cardiovascular disease
Age is the single biggest risk factor for cardiovascular disease
(CVD). The annual incidence of CVD, deﬁned as coronary artery
disease, stroke, heart failure or claudication, at age 85–94y is 10-
fold higher than at age 45–54y (Mozaffarian et al., 2015). Ageing
itself is accompanied by an increase in the prevalence of other CVD
risk factors, particularly hypertension, which affects 7% of adults
<40y and two-thirds of the over 60y (Ong et al., 2007). Lifetime
risks of CVD and hypertension for CVD-free 40y-old are 50% and
85% respectively, whilst over 30% of global mortality is attributable
to CVD (Lakatta, 2015). These disorders thus constitute a huge dis-
ease burden in the ageing population and a major limiting factor on
health span. Distinguishing the role of ageing per se in CVD patho-
genesis versus cumulative exposure to other risk factors is complex.
Ageing animal models generally do not manifest overt CVD unless
exposed to other CVD precipitants, such as high fat diet, empha-
sising the importance of the interaction between ageing and other
environmental factors.
Nevertheless, evidence that molecular mechanisms of ageing
are potentially modiﬁable contributors to CVD comes from several
observations: Firstly, known cellular and molecular antecedents of
CVD are upregulated with age in animals and in apparently healthy
humans (Lakatta, 2015). Secondly, diseased human vessels mani-
fest ‘ageing-related’ phenomena (e.g. telomere shortening (Ogami
et al., 2004), senescence (Minamino et al., 2002) and DNA dam-
age (Matthews et al., 2006)) implying that CVD pathologies are in
some respects a form of accelerated ageing. Thirdly, genetic or phar-
macological manipulation of some ageing mechanisms modulates
markers of vascular health in animal models (LaRocca et al., 2013;
Csiszar et al., 2007).
At the functional level, ageing leads to arterial stiffening and
impaired vasodilatory responses, phenomena that progress from
age 40–50y and contribute to the onset of hypertension (Harvey
et al., 2015; Sun, 2015). Hypertension is a major risk factor for
atherosclerosis and cardiac failure, but ageing is accompanied
by increased risks of these pathologies independently of blood
pressure. The biggest single contributor to ageing-associated car-
diovascular morbidity and mortality is atherosclerosis, responsible
for myocardial infarction, angina, ischaemic stroke and periph-
eral vascular disease (Mozaffarian et al., 2015). The roles of ageing
mechanisms in atherosclerosis are consequently considered here.
At the cellular level, ageing-induced changes in endothe-
lium seem particularly important for promoting atherosclerosis.
Atherosclerosis consists of the accumulation of lipid-laden
macrophages and inﬂammatory cells in the arterial wall, lead-
ing to vessel stenosis, superimposed thrombosis and occlusion.
Healthy endothelium maintains a vasodilatory, antithrombotic,
anti-inﬂammatory arterial luminal surface that retards this pro-
cess (Seals et al., 2014). Production of the vasodilator nitric oxide
(NO) by endothelial cells is key to the atheroprotective phenotype
and impaired endothelial-dependent vasodilation is an indepen-
dent predictor of atherosclerotic CVD (Lerman and Zeiher, 2005).
Ageing is accompanied by a reduction in endothelial NO-dependent
vasodilatation in animals (Csiszar et al., 2007; Tschudi et al., 1996)
and healthy non-hypertensive humans (Celermajer et al., 1994;
Donato et al., 2007), implying that ageing per se increases endothe-
lial vulnerability to atherosclerosis.
Of the molecular ageing mechanisms implicated in the devel-
opment of CVD and atherosclerosis in particular, oxidative stress
appears to play a central role. An extensive body of literature
describes the contribution of oxidative stress to atherosclerotic
plaque development via endothelial injury, inﬂammation, leuco-
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yte recruitment and lipid modiﬁcation, as reviewed elsewhere
Madamanchi et al., 2005). Ageing is accompanied by elevated
xidative stress in the arteries of rodents (Csiszar et al., 2007;
ngvari et al., 2007) and primates (Ungvari et al., 2011a). Although
linical measurement of vascular oxidative stress in vivo is not
ossible, endothelial cells isolated from arteries of healthy older
en  have increased concentrations of nitrotyrosine, a marker of
xidative stress, compared to younger men  (Donato et al., 2007).
ontributors to increased vascular ROS generation identiﬁed in age-
ng animals include vascular NADPH oxidases (NOX) (Trott et al.,
011) and mitochondrial dysfunction (Ungvari et al., 2007), as
ell as insufﬁcient activation of protective antioxidant pathways
uch as the antioxidant transcription factor Nrf2 (Ungvari et al.,
011b). Since Nrf2 is involved in mitochondrial biogenesis insuf-
cient activation of this transcription factor could have negative
onsequences for mitochondrial function and increase ROS produc-
ion (Wan  et al., 2012). Studies of endothelial cells isolated from
lder men  without vascular disease, diabetes or hypertension con-
rm that vascular NOX expression also increases in human ageing
Donato et al., 2007).
In endothelial cells oxidation of tetrahydrobiopterin, the cofac-
or for endothelial nitric oxide synthase (eNOS), causes uncoupling
f eNOS activity resulting in NO deﬁciency and further superoxide
eneration (Seals et al., 2014). Superoxide in turn reacts with NO,
educing NO bioavailability. A role for oxidative stress in ageing-
ssociated endothelial dysfunction is demonstrated by the ﬁnding
hat ROS scavengers restore endothelial vasodilatory responses in
geing rats (Tatchum-Talom and Martin, 2004).
Hypertension, hyperglycaemia and other proatherosclerotic
nsults increase vascular cell oxidative stress in vitro and in ani-
als (Touyz, 2004), thus at the molecular level may  mimic  and
ummate with the effects of ageing. Although clinical trials of anti-
xidants have found no beneﬁt in patients with CVD, this may  be
ecause established CVD is too late a stage at which to intervene, or
ecause the antioxidants used were ineffective (Seals et al., 2014;
ouyz, 2004; Dai et al., 2012).
Inﬂammation and oxidative stress are closely related in age-
elated vascular disease. Ageing rodents and primates have
ncreased vascular NF-B expression (Ungvari et al., 2011a; Csiszar
t al., 2008), accompanied by upregulation of proatherosclerotic
F-B target molecules such as the leukocyte adhesion molecule
CAM-1 (Csiszar et al., 2007). Ex vivo endothelial cells isolated from
ealthy older men  also manifest increased NF-B and inﬂamma-
ory cytokine (IL6, TNF and monocyte chemoattractant protein-1)
xpression, correlating with impaired vasodilator function (Donato
t al., 2008). Oxidative stress increases NF-B expression and
ntioxidants reverse the upregulation of NF-B in arteries of age-
ng rats (Ungvari et al., 2007). However, vascular inﬂammation is a
ause as well as a consequence of oxidative stress since TNF upreg-
lates vascular NOX expression (Csiszar et al., 2007). Inﬂammation
s thus a potentially important therapeutic target for prevention
f adverse vascular ageing. Indeed, administration of the TNF
ntagonist etanercept attenuated the adverse effects of ageing on
ndothelial dilatory function, ROS production and ICAM expression
n arteries of rats (Csiszar et al., 2007). Improvements in endothe-
ial vasodilator function have also been reported with etanercept
nd salsalate (an NF-B antagonist) in some, but not all studies of
iddle-aged and elderly participants (Seals et al., 2014).
Oxidative DNA damage (8-oxodG), telomere shortening, activa-
ion of the DNA damage response and senescence are evident in
therosclerotic lesions from clinical specimens (Minamino et al.,
002; Matthews et al., 2006; Wang and Bennett, 2012). Endothe-
ial telomere length also declined more rapidly with age in human
liac arteries compared to less atherosclerotic-prone internal tho-
acic arteries (Chang and Harley, 1995). Whether these molecular
geing phenomena play a major role in accelerating atheroscle-nd Development 160 (2016) 69–92
rosis or are simply acting as markers of vascular stress/injury is
currently unclear. However, vascular cell senescence is consid-
ered a proatherosclerotic phenotype; in addition to the presumed
detrimental effects of senescence on vascular repair capacity,
in vitro senescent endothelial cells and vascular smooth mus-
cle cells upregulate expression of inﬂammatory cytokines (IL-6,
MCP1) and adhesion molecules (ICAM1) known to be important in
atherosclerosis (Minamino et al., 2002; Wang and Bennett, 2012).
Impaired autophagy is another ageing-associated process impli-
cated in vascular disease; arteries from ageing mice and endothelial
cells isolated from older humans have lower expression of Beclin1
and accumulation of the autophagy-cleared protein p62 (LaRocca
et al., 2012). Inhibition and stimulation of autophagy in cultured
endothelial cells respectively inhibit and improve nitric oxide
bioavailability (Nussenzweig et al., 2015). Furthermore, treatment
of ageing mice with the autophagy stimulators trehalose or spermi-
dine restored endothelial function, attenuated vascular oxidative
stress and prevented arterial stiffening (LaRocca et al., 2013, 2012).
4.3. Type 2 diabetes mellitus (T2DM)
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disor-
der with an estimated global prevalence that has increased from
4.7% of the adult population in 1980 to 8.5% in 2014 (World Health
Organisation diabetes fact sheet 2016). Similarly, there has been
a signiﬁcant increase in the incidence of T2DM in both children
and adolescents (Amutha and Mohan, 2016). T2DM is a complex,
multifactorial disease although the primary driver in the observed
global increase in T2DM across all age-classes is obesity, primar-
ily central visceral adiposity In addition, the risk of developing
metabolic syndrome and T2DM also increases signiﬁcantly with
advancing age (Twito et al., 2015; Gatineau et al., 2014). T2DM
is characterized by insulin resistance across multiple tissues, an
inability to regulate hepatic glucose production effectively, and
an impairment in insulin secretion due to beta cell dysfunction
and ultimately to beta cell failure (Mahler and Adler, 1999). These
pathological changes ultimately result in an inability to regu-
late blood glucose levels, leading to a chronic elevation in blood
glucose levels, termed hyperglycaemia (Mahler and Adler, 1999;
Scheen, 2003). Hyperglycaemia can induce widespread damage to
blood vessels, particularly the microvascular leading to nephropa-
thy, neuropathy, retinopathy and signiﬁcantly increases the risk of
developing stroke, coronary heart disease, peripheral and arterial
disease (Adler et al., 2003; Cade, 2008; Dyck et al., 1993; Orchard
et al., 1990). Insulin resistance has also been implicated in increased
risk of non-alcoholic fatty-liver disease (Wild et al., 2016), and in the
development of various cancers, including some colon, liver, pan-
creatic and breast cancers (reviewed in (Tsugane and Inoue, 2010;
O’Neill and O’Driscoll, 2015)). In addition, patients suffering from
T2DM have a greater incidence of mild cognitive impairment (MCI)
relative to people without T2DM, and accelerated development of
AD (reviewed in (Barbagallo and Dominguez, 2014)). This may have
a signiﬁcantly higher risk of developing AD (Whitmer, 2007; Mittal
and Katare, 2016).
While the precise molecular mechanisms underlying T2DM are
not completely understood, several mechanisms associated with
ageing also appear intimately linked to the development of T2DM.
Ageing and obesity are both considered to play major roles in
the development of T2DM, through the development of systemic
inﬂammation. Chronic inﬂammation and the inﬁltration of inﬂam-
matory cells into the pancreatic islets can reduce insulin secretion
through beta cell dysfunction and ultimately loss of insulin produc-
ing beta cells through apoptosis (Keane et al., 2015). Pancreatic 
cell dysfunction can also result in increased production of various
cytokines by beta cells, thus further exacerbating the inﬂammatory
state. For example, activation of inﬂammatory signalling pathways,
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uch as IKK/NF-B (Inhibitor of nuclear factor kappa-B kinase
ubunit beta/nuclear factor B) in within the CNS can result in
oth insulin resistance and impaired insulin release from beta cells
Cai, 2009; Lumeng and Saltiel, 2011; Kang et al., 2009; Calegari
t al., 2011; Purkayastha et al., 2011). The activity of JNK (c-Jun
-terminal kinase) and NF-B-mediated inﬂammatory pathways
re up-regulated in obese individuals, in association with increased
evels of expression of downstream cytokines, such as TNF- and
L-6. Consequently, both IL-6 and CRP (C-reactive protein), a protein
roduced by the liver in response to systemic inﬂammation, have
een employed as robust predictors for T2DM risk (Pradhan et al.,
001; Spranger et al., 2003; Wang et al., 2013). These data are fur-
her supported by studies in genetic and dietary mouse models of
besity, which demonstrate that obesity can induce inﬂammation
ithin adipose tissue and liver leading to the production of inﬂam-
atory mediators such as IL-6 and MCP-1 (chemokine monocyte
hemotactic protein-1). Furthermore, adipocytes produce TNF-
hich can further contribute to insulin resistance (see review (Jin
nd Patti, 2009)). In a clinical trial with T2DM patients, salicylate,
n IKK inhibitor, was shown to be beneﬁcial and to improve gly-
aemia in patients, further demonstrating the role of inﬂammation
n T2DM (Goldﬁne et al., 2013).
Cellular senescence within the beta cells has also recently been
mplicated as a potential factor underlying the pathogenesis of
iabetes in various mouse models. The cell cycle inhibitor p27
Cdkn1b), a marker of senescence, increased in pancreatic -cells
n genetic mouse models of T2DM, genetic activation of p27 within
he pancreas induced diabetes in mice, and p27 deletion increased
nsulin secretion and islet mass through an increase in beta cell
umber in mouse models of T2DM (Uchida et al., 2005). Similarly,
n mice harbouring a combination of non-homologous end join-
ng deﬁciency with a hypomorphic p53 mutation and abrogation
f apoptosis, the burden of senescent cells increases rapidly and
s associated with -cell dysfunction and an overt diabetic phe-
otype by 3–5 months of age (Tavana et al., 2009). This appears
o be an accelerated model of age-associated diabetes and is con-
istent with the hypothesis that cellular senescence of beta cells
ay  be an important factor in beta cell dysfunction. In addition,
16INK4A which increases in expression in mice during ageing was
hown to impair both proliferation and regeneration potential of
slets in mice, possibly by inducing senescence (Krishnamurthy
t al., 2006). However, although these mouse models suggest that
ellular senescence may  be important in the pathology of T2DM,
 role for pancreatic islet senescence in human T2DM is cur-
ently unproven. There is widespread support for ROS-induced
xidative damage being an important pathogenic process in the
evelopment of insulin resistance, beta cell dysfunction and ulti-
ately in the development of T2DM and many of its pathological
equela (for review see (Wright et al., 2006)).In diabetic patients,
asting plasma levels of nitrotyrosine were elevated when com-
ared to non-diabetics and nitrotyrosine levels were correlated
ith post-prandial hyperglycaemia (Ceriello et al., 2002). In addi-
ion, the beta cell dysfunction has been linked to oxidative damage
o mitochondrial membranes, which may  in turn induce mito-
hondrial dysfunction and ultimately apoptosis within the beta
ells (Ma  et al., 2011). In addition, the accumulation of human
mylin seen in T2DM patients has been shown to induce beta
ell loss apparently by inducing mitochondrial dysfunction and
ncreasing ROS production (Lim et al., 2010). In elderly humans
ubjects, with insulin resistance in muscle, mitochondrial oxidative
ctivity and mitochondrial adenosine triphosphate (ATP) synthesis
ere decreased, implicating mitochondrial dysfunction in T2DMPetersen et al., 2003). Insulin resistance, in patients with metabolic
yndrome, has also been linked to a decrease in the number of mito-
hondrial DNA (mtDNA) copy number, implicating dysfunctional
itochondrial biogenesis in this disease (Gianotti et al., 2008).nd Development 160 (2016) 69–92 77
Skeletal muscle biopsies have provided evidence that various tran-
scriptional factors (e.g. PPAR gamma coactivator 1-alpha and-beta
(PGC1-alpha/PPARGC1 and PGC1-beta/PERC), coactivators of NRF-
1 (nuclear respiratory factor-1) and PPAR gamma-dependent) are
decreased in diabetic patients ((Patti et al., 2003), reviewed in
(Jin and Patti, 2009)). Given that all are associated with mito-
chondrial maintenance and biogenesis (Perez-Schindler and Philp,
2015), suggests that reduced nuclear-encoded mitochondrial gene
expression may  be a factor in T2DM. The transcriptional co-
activators PGC1 and PGC1 are also decreased by age, further
linking ageing to the mitochondrial dysfunction that occurs in
T2DM (Ling et al., 2004). In addition, muscle mitochondrial from
diabetic patients tend to be relatively smaller and found at a
lower density (reduced number per unit volume (Kelley et al.,
2002)). Moreover, in a mouse model of T2DM (the db/db mice)
heart mitochondrial uncoupling was shown to occur, leading to
decreased oxidative phosphorylation capacity and increased ROS
production and lipid peroxidation (Boudina et al., 2007). The
non-obese diabetic Goto-Kakizaki rat has also been reported to
have increased skeletal muscle oxidative stress and mitochondrial
dysfunction (Armour et al., 2009). During ageing the accumula-
tion of mitochondrial DNA mutations and deletions may  impair
the electron respiratory chain, further increasing ROS production.
Mitochondrial dysfunction has also been implicated in age-related
insulin resistance, thus promoting a vicious metabolic cycle and
increasing the risk of T2DM (Petersen et al., 2003; Ye, 2013;
Reznick et al., 2007). These processes do not act in isolation, and
many inﬂammatory processes may  also be activated, with several
pro-inﬂammatory cytokines (as stated above) expressed, further
impairing insulin signalling, beta cell function and the development
of age-related insulin resistance and T2DM (Styskal et al., 2012;
Park et al., 2014).
The evidence that a loss in proteostasis during ageing has been
gaining momentum in the recent past (Labbadia and Morimoto,
2014). Similarly, a disruption in various components of the pro-
teasomal machinery has been reported in T2DM. For example, the
build-up of toxic amyloid polypeptides in the beta cells of T2DM
patients is associated with elevated levels of polyubiquitinated
proteins and the deﬁciency of an enzyme (ubiquitin carboxyl-
terminal esterase L1; UCHL1) involved in the deubiquitination of
proteins (Costes et al., 2014). The loss of Uchl1 with beta cells of
transgenic mice overexpressing human islet amyloid polypeptide
increased the onset of overt diabetes relative to mice wild-type for
Uchl1 (Costes et al., 2014). Interestingly, the loss of Uchl1 in trans-
genic mice further intensiﬁed the defective autophagy/lysosomal
phenotype already observed in the transgenic mice. Importantly,
mitochondrial dysfunction and endoplasmic reticulum (ER) stress
promote an increase in autophagy, a cellular mechanism impor-
tant to restore intracellular homeostasis (Butler and Bahr, 2006;
Jung and Lee, 2010). In turn, autophagy blockade leads to the accu-
mulation of mitochondria with excessive ROS production, which
promotes NLRP3 (NOD-like receptor family, pyrin domain contain-
ing 3) inﬂammasome activation (Zhou et al., 2011). When ER stress
and mitochondrial dysfunction, alongside the consequent produc-
tion of ROS, are prolonged, failure of the autophagy machinery
may  occur, further promoting the development of the metabolic
syndrome and diabetes (Cai and Liu, 2012; Gonzalez et al., 2011;
Muriach et al., 2014). Supporting this hypothesis, there is a positive
correlation between ROS levels, ER stress and autophagy markers in
leukocytes from T2DM patients (Rovira-Llopis et al., 2015). In addi-
tion, in mice fed with a high-fat diet, autophagic ﬂux was shown
to be increased in pancreatic  cells as a reaction to the induction
of ER stress (Chu et al., 2015). As further evidence that autophagy
may  play an important role in the development of T2DM, studies in
-cells from diabetic db/db and C57BL/6 mice fed with high-fat diet,
showed the active formation of autophagosomes (Gonzalez et al.,
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011). In addition, a  cell-speciﬁc deletion of Atg7 in human islet
myloid polypeptide (hIAPP) knock-in mice signiﬁcantly impaired
lucose tolerance on a high fat diet (Shigihara et al., 2014). More-
ver, pancreatic samples from subjects with T2DM demonstrated
he presence of a high number of dead -cells in diabetic islets
ith massive vacuole overload, suggesting autophagy-associated
ell death (Marchetti and Masini, 2009).
.4. Neurodegenerative diseases
Neurodegenerative disorders such as Alzheimer’s and Parkin-
on’s disease are also increased with age (Szewczyk-Krolikowski
t al., 2014; Riedel et al., 2016). As neurons age, they show signs of
ncreased oxidative stress, disturbances in mitochondrial function,
nd accumulation of misfolded proteins, which are exacerbated in
lzheimer’s disease (AD), and in Parkinson’s disease (PD). However,
 direct link between mechanisms of ageing and the onset of such
eurodegenerative disorders is still missing.
.4.1. Alzheimer’s disease
Alzheimer disease (AD) is the neurodegenerative disorder most
sually associated to age-related dementia and is etiologically
ultifactorial (Talwar et al., 2015). Histologically, AD is character-
zed by extensive neurodegeneration, extracellular deposition of
myloid- peptide (A)  forming senile plaques, and intraneuronal
ccumulations of hyperphosphorylated microtubule-associated
rotein tau, the neuroﬁbrillary tangles (NFTs) (Dickson et al., 1988).
 is a small protein formed upon cleavage of amyloid precursor
rotein (APP) by -site APP cleaving enzyme 1 (BACE1) and -
ecretase, a protease complex containing presenilins 1 and 2 (PS1,
S2) (Cole and Vassar, 2007; Selkoe, 1998). Accumulation and mis-
olding of A both intracellularly in neurons and extracellularly as
ligomers or A aggregates lead to the pathological cascade of AD
Cerasoli et al., 2015). Indeed, oligomeric and ﬁbrillary A, usu-
lly cleared by myeloid cells, also activate these cells leading to a
euroinﬂammatory response (Manocha et al., 2016), which may
ontribute to neurodegeneration as stated below. Although A has
een considered the origin of the disease for many years, accumu-
ating evidence has demonstrated that hyperphosphorylated tau
s well as the close relationship between tau and A abnormal
etabolism may  also have a role during the onset and progres-
ion of the disease (reviewed by (Llorens-Marítin et al., 2014)).
ne common molecule involved in these two main hallmarks,
enile plaques/A and neuroﬁbrillary tangles/tau, is GSK-3.  Sev-
ral canonical substrates of GSK-3 are involved in A production
nd PS1 function both in rodent models and in vitro (Llorens-
arítin et al., 2014), and inhibition of GSK-3 has been reported
o reduce A pathology in mice (Ly et al., 2013). In parallel, the
ction of GSK-3,  together with other tau kinases, is necessary
or the phosphorylation of tau in the pre-tangle stage of A in
odents (reviewed by (Llorens-Marítin et al., 2014)). Thus, it is not
urprising that the activity of GSK-3 is a key factor widely used
o model AD in rodents (Gómez-Sintes et al., 2011). Even more
nteresting, GSK-3 dysregulation has been found in ageing-related
nﬂammation establishing an important link between ageing and
D (Zhou et al., 2013). Hyperphosphorylation of tau takes place
oth in AD and in neuroimﬂammation due to GSK3 hyperactivity
Lucas et al., 2001). GSK3 promotes secretion of proimmﬂamatory
ytokines (such as IL-6) together with the hyperphosphorilation
f tau, leading to increased cell death and generating further neu-
oinﬂammation (Fuster-Matanzo et al., 2013). However, all these
ata are in murine models of AD. In human subjects increased
ctivity of neuronal GSK-3 has been found in AD brains (DaRocha-
outo et al., 2012). In addition, although the overexpression of
otal GSK-3 in frontal cortex of AD human brains compared to
ealthy age-matched controls did not reach statistical signiﬁcance,nd Development 160 (2016) 69–92
the phosphorylated and active form of GSK-3  (pTyr216), showed
to be markedly increased over control subjects and co-localized
with several somatodendritic phosphor-tau epitopes (Leroy et al.,
2007). This co-localization was  described only into discrete cellular
compartments, such as the autophagosomes (Taelman et al., 2010).
Inﬂammation has long been considered a hallmark of AD and
highly involved in the etiopathology of the disease (Meraz-Ríos
et al., 2013). Pro-inﬂammatory and immune markers are aberrantly
expressed in the brain of healthy elderly (Schuitemaker et al., 2012;
Cribbs et al., 2012). Within the CNS, microglial cells, also called
brain macrophages, are responsible for the constantly immune
surveillance of brain and spinal cord parenchyma, and become acti-
vated upon challenge. They are the main producers of inﬂammatory
molecules to ﬁght pathogenic agents or clear damage (for review
see (Fernandes et al., 2014)). There is evidence that microglia is
primed in the aged brain, thereby developing exacerbated and
prolonged neuroinﬂammatory response after stimulation (Perry
et al., 2010; Norden and Godbout, 2013). In line with this microglia
over-activation has been reported in AD brains (Mandrekar and
Landreth, 2010). In addition the involvement of inﬂammation in
cognitive decline is supported by studies in AD animal models
showing that blockade of IL-1 (Kitazawa et al., 2011) or deletion
of TNFR1 gene (McAlpine et al., 2009) rescued animal cognitive
deﬁcits associated with AD progression. However, this seems a
rather early event since the use of anti-inﬂammatory drugs showed
a beneﬁcial effect only if administered in very recent stages of dis-
ease or even before disease onset (Stewart et al., 1997). Moreover,
inﬂammation has also been implicated in A accumulation through
modulation of BACE activity. Both deletion of Tenascin (Xie et al.,
2013), an extracellular matrix protein that is upregulated in inﬂam-
mation, or of TNRF1 (He et al., 2007) genes were shown to decrease
BACE activity in in vivo models of AD. Furthermore, expression
of p38 MAPK, a common inﬂammatory cascade, regulates BACE
fate. While ROS-mediated BACE activation occurs downstream p38
MAPK activation (Tamagno et al., 2005), the reduction of p38 MAPK
expression facilitate BACE lysosomal degradation (Schnöder et al.,
2016).
In parallel with the over-activated microglia the presence of
microglia showing abnormal morphology typical of senescent cells
has also been described in the ageing human brain with frag-
mented cytoplasmic processes (e.g. cytorrhexis) and spheroidal
swellings in their ramiﬁcations (Streit et al., 2009). Similar alter-
ations have also been reported in samples from AD patients (Streit
et al., 2009). In addition rodent microglia aged in culture showed
loss of ability to migrate and phagocyte (Caldeira et al., 2014),
similarly to what observed with other innate immune cells with
age (Hearps et al., 2012) and this may  be the case in AD patients.
In vivo studies using animal models of AD showed that microglia
from old mice, but not from young ones, have decreased expres-
sion of both A-binding scavenger receptors and A degrading
enzymes when compared with their littermate controls, but higher
levels of cytokine release (Hickman et al., 2008). While ﬁbrillar A
promoted microglia phagocytosis, oligomeric A reduced this abil-
ity, while enhancing a higher inﬂammatory response (Pan et al.,
2011), further corroborating that microglial phagocytosis is neg-
atively correlated with inﬂammatory reactivity. Examination of
3 patients affected by AD showed some clearance of plaques by
microglia phagocytosis only following stimulation with A immu-
nization (Nicoll et al., 2006). Interestingly, AD patients subjected
to immunization for aggregated A (Rampelli et al., 2013) showed
reduced cognitive impairment (Hock et al., 2003), corroborating
that microglia may  undergo loss of function in AD progression.Several lines of evidence showed that mutations in mitochon-
drial DNA and net production of reactive oxygen species (ROS)
have a central role not only in the process of brain ageing but also
in the pathogenesis of neurodegenerative disorders including AD
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Lin and Beal, 2006). AD patients showed reduced levels of anti-
xidant defence mechanisms (Andersen, 2004). In mouse models,
D neuronal oxidative damage occurs earlier before A deposi-
ion and plaque formation (Pratico et al., 2001), and is associated
ith up-regulation of genes related to mitochondrial metabolism
nd apoptosis (Reddy et al., 2004). Indeed, oxidative stress was
eported as a cause of increased A levels and plaque deposition
n both in vitro and in vivo AD-models (Velliquette et al., 2005;
usciglio et al., 2002). Moreover, oxidative stress also was shown
o increase the expression of BACE through activation of JNK and
38 MAPK (Tamagno et al., 2005), and lead to aberrant tau hyper-
hosphorylation by activation of GSK-3 (Lovell et al., 2004). More
mportantly a higher number of mutations were found in mito-
hondrial DNA from AD patients compared to controls (Coskun
t al., 2004), and related with A deposition within damaged mito-
hondria of AD patients (Hirai et al., 2001). It has been described
hat A not only potentiates NO synthesis but also that inhibits
ey mitochondrial enzymes, namely complex IV and cytochrome c,
hile Tau inhibits complex I (reviewed in (Querfurth and LaFerla,
010)), further increasing oxidative stress and mitochondria fail-
re. In accordance, in AD patients structural changes caused by A
n mitochondria resulted in increased mitochondrial fragmenta-
ion, decreased mitochondrial fusion, mitochondrial dysfunction,
nd synaptic damage (Reddy et al., 2010; Manczak et al., 2006).
Autophagy-related pathology has been noted in late-onset neu-
odegenerative diseases including AD (Nixon and Cataldo, 2006).
t has been postulated that the age-dependent onset of neurode-
enerative diseases most likely correlates with the age-dependent
ecline of autophagic activity. Recent reports in mice deﬁcient for
tg5 or Atg7 conﬁrmed that impairment of autophagy promoted
euronal loss following accumulation of cytoplasmic inclusion bod-
es in neurons (Hara et al., 2006; Komatsu et al., 2006). Impairment
f lysosomes function in cortical neurons of AD patients was ﬁrst
escribed in early 90 s (Cataldo et al., 1991). More recently these
ave been described as endosome or autophagosomal anomalies
nd impaired lysosome biogenesis (Nixon and Cataldo, 2006) with
ccumulation of autophagosome vacuoles in swollen dystrophic
eurites of affected neurons due to impaired axonal transport of
utophagy/lysosomal-related compartments as described in vitro
n primary mouse cortical neurons (Lee et al., 2011). Moreover,
eclin1 has been shown to be deﬁcient in brain samples from
D patients (Jaeger et al., 2010). Interestingly, mutations of PS1,
 common cause for early-onset of familiar AD, led to markedly
efective lysosomal acidiﬁcation and autolysosomal maturation
otentiating the autophagic/lysosomal, amyloid, and tau patholo-
ies observed in animal model and AD patients (Cataldo et al.,
004). Also changes in the degradation of speciﬁc AD-related pro-
eins have been described, namely by the presence of ubiquitinated
orms of tau and A as the major components of their aggregates in
rain samples of AD patients (Perry et al., 1987). Interestingly, the
se of rapamycin, known to enhance autophagy, before AD devel-
pment, delayed and reduced AD phenotype, while rapamycin
reatment after AD emergence had no signiﬁcant effect (Majumder
t al., 2011), suggesting that altered autophagy may  have a major
ole in AD development.
.4.2. Parkinson’s disease (PD)
PD is a chronic, incurable disorder, whose incidence increase
ith age and affects 1–3% of the elderly population worldwide
Szewczyk-Krolikowski et al., 2014; Johnson and Bobrovskaya,
015). Histopathologically, PD is characterized by the loss of
opaminergic neurons of the substantia nigra and locus coeruleus
n parallel with astrocytosis and microgliosis. These events have
een associated with the presence of proteinaceous intracellular
ggregates called Lewy bodies, comprised primarily of -synuclein
Syme et al., 2002). A new deﬁnition of PD should consider it asnd Development 160 (2016) 69–92 79
a multisystem synucleinopathy with pathology extending beyond
the conﬁnes of the central nervous system (CNS) and clinical
manifestations concerning dopamine cell loss (Stern et al., 2011).
Non-dopaminergic and non-motor symptoms of PD are some-
times present before diagnosis and almost inevitably arise and
strengthen with disease progression. Indeed, non-motor symp-
toms dominate the clinical picture of advanced PD and contribute
to severe disability, impaired quality of life, and shortened life
expectancy. By contrast with the dopaminergic symptoms of the
disease, for which treatment is available, non-motor symptoms are
often poorly recognised and inadequately treated (Chaudhuri et al.,
2006).
Ageing and PD share several physiological changes as well as
numerous cellular and molecular mechanisms, including oxida-
tive stress and mitochondria dysfunction, proteasome failure and
impaired autophagy. However, it is unknown whether the path-
ways underpinning these alterations are the same. Involvement of
mitochondria dysfunction in PD was ﬁrst addressed when MPTP (1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine), whose metabolite
MPP+ inhibits complex-I of the mitochondrial electron-transport
chain, caused a parkinsonism syndrome in adulterated drug
abusers (Lee et al., 2012). Further research showed mitochondria
complex-I deﬁciency and glutathione depletion in the substantia
nigra of patients with idiopathic or pre-symptomatic PD (Schapira
et al., 1989), suggesting an increased mitochondrial dysfunction
and reduced anti-oxidant capacity in these patients. In addition,
several PD-related genes have been associated with mitochon-
dria/oxidative stress damage. Abnormal -synuclein accumulation
directly alters mitochondria morphology and increases superox-
ide formation in SH-SY5Y neuroblastoma cell line (Perfeito et al.,
2014), also boosting MPTP-induced nigral pathology in human
-synuclein transgenic mice (Song et al., 2004), while mutant
-synuclein co-localizes with degenerating mitochondria also in
-synuclein transgenic mice suggesting a possible direct damaging
effect (Martin et al., 2006).
The proteasome activity is also altered in PD. Expression of
mutant -synuclein promotes the formation of ﬁlaments which
interact directly with the 20S core of the proteasome and decrease
its proteolytic activity (Lindersson et al., 2004), which is counter-
acted by the expression of the E3 ligase Parkin (Petrucelli et al.,
2002). While mutations in -synuclein cause autosomal dominant
PD, mutations in Parkin, which reduces -synuclein ubiquitination
and promotes Lewi bodies formation, cause autosomal recessive PD
(Hardy, 2003). Furthermore, Parkin also modulates the pro-survival
signalling through EGFR-Akt-mTOR pathway (Fallon et al., 2006),
which is decreased in disease-related brain regions of PD patients
(Iwakura et al., 2005), and has a major role in mitochondria number,
maintenance and mitophagy (Bertolin et al., 2015). Interestingly, a
recent study on adult Drosophila melanogaster showed that ubiq-
uitous or neuron-speciﬁc up-regulation of Parkin extends lifespan
(Rana et al., 2013).
Once more, autophagosome-like structures are also increased
in PD (Stefanis, 2005), suggestive of defective autophagy both at
the early stages and in later lysosomal clearance and linking PD
with ageing. Mitophagy failure is a hallmark of PD and justiﬁed
by mutations of Parkin and PINK1, which are associated to auto-
somal recessive cases of PD (Gasser, 2009). PINK1, a sensor of
mitochondrial membrane polarization, is constitutively cleaved but
becomes stabilized in the outer mitochondria membrane when
mitochondria function is comprised (Abeliovich, 2010). This enable
Parkin to ubiquitinate exposed membrane proteins, recruiting LC3
and initiating mitophagy of damaged mitocondria (Narendra et al.,
2010). PD-related mutations in Parkin and PINK1 impair mitophagy
causing accumulation of damaged mitochondria which signals for
apoptotic events. Also mutations in -synuclein (Cuervo et al.,
2004), in familial PD, or changes of -synuclein by dopamine
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Xilouri et al., 2009), in sporadic PD, impairs chaperone-mediated
utophagy blocking not only its own uptake into lysosomes but that
f other substrates. Autophagy induction by beclin 1 gene transfer
r rapamycin ameliorated pathology in some -synuclein PD mod-
ls (Dadakhujaev et al., 2010) but not in others (Zhu et al., 2007),
uggesting that further attention should be given to autophagy
efects in PD.
Inﬂammatory-associated features are also observed in PD and
elated to its ageing increased susceptibility. Several reports using
ET imaging studies revealed increased microglial activation in in
ivo PD patients (Surendranathan et al., 2015), being correlated
ith midbrain and dopaminergic loss in the early stages of PD
Ouchi et al., 2005). Further studies using in vivo models of PD
evealed that -synuclein was the main trigger of microglia acti-
ation through induction of MHC  class II expression (Harms et al.,
013) and Toll-like receptor-2 (TLR2) engagement in these cells
Kim et al., 2013). This activation was further corroborated by the
resence of increased levels of inﬂammatory cytokines in brain
amples of post-mortem PD brains (Mogi et al., 1994), as well as in
olony stimulating factors and serum samples of PD patients (Hu
t al., 2015).
. Interventions
The ﬁrst evidence that it may  be possible to delay ageing in
ore than one tissue simultaneously comes from studies employ-
ng dietary restriction (DR); DR is deﬁned here as a measured
ecrease in calories, macronutrients or micronutrients compared
o that eaten by animals maintained on an ad libitum (AL) control
iet. There is variety in terminology and experimental paradigms
xplored, but the reduction of calories to 30–50% below ad libi-
um (AL) levels is most frequently used (Speakman and Mitchell,
011; Chung et al., 2013). The positive effects of DR on both
ifespan and health span have been recognised for nearly a cen-
ury (Osborne et al., 1917). DR is undoubtedly the most widely
sed experimental intervention in ageing research, demonstrating
leiotropic beneﬁcial effects on several biological systems. Proba-
ly the most spectacular effect within this expanding research area
s DR-induced increase of median and maximum lifespan observed
n a wide number of organisms (Fontana and Partridge, 2015).
owever, what is also becoming clear is that the effects of DR on
ongevity may  not actually be universal, with studies in a num-
er of organisms not demonstrating an increase in lifespan on DR
reviewed in (Mulvey et al., 2014; Swindell, 2012)). For example, it
s now well established that genetic background can inﬂuence the
xtent of DR-induced longevity (Mulvey et al., 2014), with 40% DR
n recombinant inbred ILXISS mice leading to lifespan extension in
ome lines to lifespan shortening in other lines (Liao et al., 2010;
ikke et al., 2010).
Similarly, the recent DR study in rhesus monkeys performed
t the National Institute of Ageing (NIA) revealed that DR did not
mprove survival outcomes (Mattison et al., 2012; Austad, 2012),
n contrast with the ﬁndings of the study undertaken by the Wis-
onsin National Primate Research Center (WNPRC) by Coman and
olleagues (Colman et al., 2014, 2009). Several differences exist
n terms of experimental design, husbandry and dietary composi-
ion between the NIA and WNPRC studies that may  help explain
he discrepancies in terms the ability of DR to impact on lifes-
an (Partridge, 2012; Selman, 2014). DR both ameliorates and
elays a number of age-associated pathologies in a wide range
f organisms, including protection against metabolic dysfunction
e.g. insulin resistance, glucose intolerance, obesity), neurodegera-
ive disease, sarcopenia, osteoporosis and immune dysfunction
Speakman and Mitchell, 2011; Selman, 2014; Masoro, 2005). In
ddition, DR signiﬁcantly decreases the incidence and progressionnd Development 160 (2016) 69–92
of both spontaneous age-associated and experimentally-induced
cancers (Selman, 2014). Excitingly, despite the ambiguous effects
of DR on lifespan in non-human primates (discussed above), DR
induced protection in non-human primates against a number of
age-associated pathologies, including T2DM, cardiovascular dis-
ease and cancer, and has also been shown to produce a number
of favourable metabolic effects in humans (Fontana and Partridge,
2015; Mattison et al., 2012; Colman et al., 2014, 2009).
Notwithstanding the effects of DR on lifespan and health span
being established for many decades now, the precise mechanisms
driving these effects are still far from clear (Fontana and Partridge,
2015). Indeed, exactly how DR elicits its beneﬁcial affects is likely
to be highly complex, with different dietary interventions capa-
ble of exerting their effects through different mechanisms even
within a single organism (Walker et al., 2005). DR modulates several
signalling pathways and molecules known to modulate lifespan
and health span: members of sirtuin family, insulin/insulin growth
factor-1 and TOR, peroxisome proliferator activated receptor G
coactivator-1 and adenosine monophosphate activated protein
kinase (Lamming, 2014; Testa et al., 2014; Ramis et al., 2015). In
addition, DR also tends to reduce oxidative damage, preserve mito-
chondrial function during ageing, and enhance proteostasis and
stem cell function, which are all implicated in extended health span
and all affected by the various signalling pathways and molecules
described above (Fontana and Partridge, 2015).
However, despite the overall effectiveness of DR on lifespan and
health span in the laboratory, the translation of such intervention
to humans is likely to be confounded the obvious difﬁculties in
individuals all complying to a DR diet over a protracted period of
life and by the increased heterogeneity of the population. Work is
ongoing to better understand the interaction between DR and, for
example, genetic interventions that also modulate lifespan, what
components of the diet can be restricted to modulate lifespan
and health span (e.g. amino acids), without reductions in calorie
intake. Perhaps DR in combination with nutritional geometry-type
approaches (Piper et al., 2011) may  help identify optimal dietary
interventions for humans, without unwanted side-effects and the
need for life-long restriction. One other potential route to better
understand how DR acts mechanistically is through a compara-
tive approach by studying those animals that show some deviation
away from the ‘DR norm’ in terms of lifespan and health span
(Mulvey et al., 2014). That is, by studying what changes or does
not change under DR in these animals, compared to ‘positive con-
trols’, may  help give additional insights in to the mechanistic nature
of DR, and particularly relevant to humans, help understand better
the potential confounding nature of genetics on the DR response.
Pharmacological interventions are gaining place as a potential
easier alternative for compliance than DR. A number of molecules
targeting oxidative stress, autophagy, inﬂammation or the effects of
accumulation of senescence cells are emerging together with evi-
dence that they can have positive effects on more than one organ
system in delaying the ageing phenotype (Table 2) and reviewed
in (Riera and Dillin, 2015). In addition a new database of life span
studies has recently been announced, to be hosted at geroprotec-
tors.org. There is an existing catalogue of lifespan studies in animals
at http://lifespandb.sageweb.org.
Very few of these molecules have been thoroughly assessed and
testing poses considerable challenges. We  consider here two  of the
most studied candidates, rapamycin and metformin to illustrate
some of the challenges. Rapamycin targets the mTOR signalling
pathway, an important and evolutionarily conserved player in
longevity regulation and is the most extensively tested among the
molecules listed in Table 1. It has been shown to be able to delay
cancer formation in aged mice and extend their lifespan (Miller
et al., 2007; Harrison et al., 2009; Neff et al., 2013). Testing of the
compound’s effects on a wide range of functional parameters used
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Table  1
Chronic age-related diseases with corresponding disease hallmarks and mechanisms of ageing.
Tissue/cellular alterations Disease hallmarks Mechanisms of ageing
Osteoarthritis (OA) Damaged extracellular matrix
Chondrocyte senescence
(Bjedov et al., 2010)
Cartilage degeneration
Subchondral bone loss
Joint inﬂammation
Joint pain (Pyo et al.,
2013)
↑ oxidative stress (Bijlsma et al., 2011; Goldring, 2000)
↑  senescence (Brighton and Heppenstall, 1971; Yudoh et al.,
2005)
↑ mitochondrial dysfunction
↑ inﬂammation (IL-1, IL-6, TNF-) (Eisenberg et al., 2009;
Loeser et al., 2002)
↓  autophagy (Ruiz-Romero et al., 2009; Grishko et al., 2009)
Osteoporosis Imbalance between bone
formation and resorption (Sharif
et al., 2004)
↓ bone mass (Sharif
et al., 2004)
↑ oxidative stress (Sod1, Sod2, GPx, GST, NOX4) (Chang et al.,
2009; Onal et al., 2013)
↑  inﬂammation (NFkB, IL-1, IL-6, TNF-) (Kimble et al., 1995;
Lorenzo et al., 1998)
↓ autophagy (ATG7, Beclin1) (Chen et al., 2003)
Cardiovascular
diseases (CVD)
Atherosclerosis
Arterial stiffening
Compromised vasodilaton (Ong
et al., 2007; Lakatta, 2015)
Accumulation of lipid-laden
macrophages + inﬂammatory cells
(Ogami et al., 2004)
Atherosclerosis (Zhang
et al., 2010)
↑ risk of
• Myocardial infarction
• angina
• ischemic stroke
• heart failure (Zhang
et al., 2010)
↑ oxidative stress (nitrotyrosine, NOX, mitochondrial
respiration,
↓Nrf2) (Mozaffarian et al., 2015; Sun, 2015; Seals et al., 2014;
Tschudi et al., 1996; Celermajer et al., 1994)
↑ inﬂammation (NFkB, IL-1, IL-6, TNF-) (Sun, 2015; Trott
et al., 2011)
↑ senescence (IL-6, MCP1, ICAM1) (Nojiri et al., 2011)
↓  NO vasodilation (Mozaffarian et al., 2015; Matthews et al.,
2006)
↓ autophagy (Beclin1, p62 accumulation) (Goettsch et al.,
2013; Tatchum-Talom and Martin, 2004; Touyz, 2004)
Type  2 Diabetes
Melitus (T2DM)
Inefﬁcient insulin secretion
Abnormal insulin response (Wang
and Bennett, 2012)
Hyperglycemia (Wang
and Bennett, 2012;
Chang and Harley,
1995)
Hemoglobin glycation
↑  risk of
• vascular complica-
tions (i.e. stroke,
coronary heart
disease, retinopathy)
• to develop dementia
(206–209; 213–215)
↑ oxidative stress (Goldﬁne et al., 2013)
↑ inﬂammation (NFkB, IL-1, IL-6, TNF-, CRP, MCP-1) (Wild
et  al., 2016; Tsugane and Inoue, 2010; O’Neill and O’Driscoll,
2015; Barbagallo and Dominguez, 2014; Whitmer, 2007;
Mittal and Katare, 2016; Keane et al., 2015; Cai, 2009; Lumeng
and Saltiel, 2011; Kang et al., 2009; Calegari et al., 2011;
Purkayastha et al., 2011)
↑ mitochondrial dysfunction (ATP, mtDNA, PPAR) (Goldﬁne
et al., 2013; Uchida et al., 2005; Tavana et al., 2009;
Krishnamurthy et al., 2006)
↑ senescence (Calegari et al., 2011; Pradhan et al., 2001)
↓  autophagy (Armour et al., 2009; Ye, 2013; Park et al., 2014;
Zhou et al., 2011)
Alzheimer’s
disease (AD)
Extensive neurodegeneration
A deposition (senile plaques)
Tau accumulation (neuroﬁbrillary
tangles) (Rovira-Llopis et al., 2015;
Chu et al., 2015; Shigihara et al.,
2014; Marchetti and Masini, 2009)
Dementia (Muriach
et al., 2014)
↑ oxidative stress (McAlpine et al., 2009)
↑ inﬂammation (Ly et al., 2013)
↑  mitochondrial dysfunction (Xie et al., 2013)
↑  senescence (Cribbs et al., 2012; Fernandes et al., 2014; Perry
et al., 2010; Norden and Godbout, 2013; Mandrekar and
Landreth, 2010)
↑ proteasome alterations and autophagy (Pan et al., 2011;
Nicoll et al., 2006; Hock et al., 2003; Lin and Beal, 2006;
Andersen, 2004; Pratico et al., 2001; Reddy et al., 2004;
Velliquette et al., 2005)
Parkinson’s disease
(PD)
Loss of dopaminergic neurons,
astrocytes and microgliosis
Lewy bodies (-syn aggregates)
(Coskun et al., 2004; Hirai et al.,
2001)
Severe motor disability
Impaired quality of life
Shortened life
expectancy
(Querfurth and LaFerla,
2010)
↑ oxidative stress (Reddy et al., 2010; Manczak et al., 2006;
Nixon and Cataldo, 2006; Hara et al., 2006; Komatsu et al.,
2006)
↑ inﬂammation (Lindersson et al., 2004; Petrucelli et al., 2002;
Hardy, 2003; Fallon et al., 2006; Iwakura et al., 2005; Bertolin
et al., 2015)
↑ mitochondrial dysfunction (-syn, DJ-1, parkin, PINK1)
(Reddy et al., 2010; Manczak et al., 2006; Nixon and Cataldo,
2006; Hara et al., 2006; Komatsu et al., 2006)
↑ proteasome failure (Cataldo et al., 1991)
t
m
i
t
(
h
M
i
2
mo assess health status has shown positive age-dependent improve-
ent only on immune function in the T cell compartment both
n mice following rapamycin treatment (Neff et al., 2013) and in
he elderly when treated for six weeks with a rapamycin analogue
RAD001) (Mannick et al., 2014). Rapamycin has been shown to
ave stimulatory effects on locomotor behaviour (Neff et al., 2013;
iller et al., 2011; Wilkinson et al., 2012; Flynn et al., 2013) and
mproves learning and memory (Neff et al., 2013; Majumder et al.,
012; Halloran et al., 2012) across several studies using different
ouse strains and in both males and females. However, simi-↓  autophagy (LC3, Beclin-1) (Syme et al., 2002; Stern et al.,
2011; Chaudhuri et al., 2006; Lee et al., 2012; Schapira et al.,
1989; Perfeito et al., 2014)
lar effects were observed in young mice questioning whether the
effects observed were modulation of ageing per se (Neff et al., 2013).
More importantly some of the effects have not been reproducible.
For example no signiﬁcant improvement on index of cardiac func-
tion was  found in the study by Neff et al. (Neff et al., 2013) in
contrast to Flynn et al. (2013) where mice showed a signiﬁcant
improvement in the ejection fraction and signiﬁcantly less hyper-
trophy than the control group. The discrepancies may  be due to
the small size of the effect, which put into question whether the
effect is of clinical value, differences in study design (longitudi-
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Table 2
Pharmacological interventions as potential alternatives for compliance to dietary restriction (DR). A number of molecules targeting oxidative stress, autophagy, inﬂammation
or  the effects of accumulation of senescence cells are summarized, together with evidence that support their positive effects on more than one organ system in delaying the
ageing phenotype.
Molecule Target Modiﬁed ageing mechanisms Lifespan extension Healthspan with age/disease
improvement
Human  testing
Rapamycin mTORC1 Autophagy (Berger et al., 2006)
Oxidative stress (Rotte et al.,
2012; Kofman et al., 2012;
Miwa  et al., 2014)
Yes
(reviewed in
(Kaeberlein, 2014))
Cancer prevention
Increase cognition, cardiac
function, insulin sensitivity,
mobility, decreased immune
dysfunction (Neff et al., 2013;
Wilkinson et al., 2012; Flynn
et al., 2013; Fang et al., 2013)
Immunosuppression
Cancer treatment
(Hidalgo and
Rowinsky, 2000)
Prevention of
immunosenes-
cence (Mannick
et al., 2014)
Metformin Reduce hepatic glucose
production
AMPK activation (Zhou et al.,
2001)
Respiratory chain complex I
(El-Mir et al., 2000)
Autophagy
Oxidative stress
Chronic inﬂammation
(Martin-Montalvo et al., 2013)
Yes
(Martin-Montalvo
et al., 2013)
and in patients
with diabetes
(Bannister et al.,
2014)
Improved mobility, insulin
sensitivity, decreased cataract
formation, cancer
(Martin-Montalvo et al., 2013;
Yin et al., 2011; Anisimov et al.,
2005)
Type 2 diabetes
(Bosi, 2009)
Decrease in cancer
risk (Bodmer et al.,
2010)
17estradiol Estrogen receptor Oxidative stress (Gelinas et al.,
2004)
Inﬂammation (Stout et al.,
2016)
Yes, in male mice
(Harrison et al.,
2014)
Neuroprotective (Simpkins
et  al., 1997), Based on
17estradiol activity
Alzheimer’s disease, Parkinson,
CVD
Tested as
neuroprotector
with conﬂicting
outcomes (Moos
et al., 2009)
Acarbose glucosidases inhibitor in the
intestine (Harrison et al., 2014)
Reduce release of glucose
Oxidative stress (Rosen and
Osmers, 2006)
Yes (Harrison et al.,
2014)
Diabetes
Improved voluntary activity in
female mice (Harrison et al.,
2014)
Decrease Myocardial infarct
size (Minatoguchi et al., 2009)
Used for Diabetes,
reduce risk of CVD
(Standl et al., 2014)
NDGA  arachidonic acid
5-lipoxygenase inhibitor
Inﬂammation (West et al.,
2004)
Oxidative stress (Shishido
et al., 2001)
Yes (Harrison et al.,
2014; Strong et al.,
2008)
Neuroprotective (Shishido
et  al., 2001)
Increase insulin sensitivity
(Reed et al., 1999)
Anti-cancer in vitro (Youngren
et al., 2005)
Used in prostate
cancer patients
with no effects
Aspirin COX inhibitor Inﬂammation (Kopp and
Ghosh, 1994)
Oxidative stress (Podhaisky
et al., 1997)
Yes male mice only
(Strong et al., 2008)
Reduce CVD,
anti-inﬂammatory
Non steroidal
anti-inﬂammatory
and
anti-thrombotic
(prevention of CVD
and stroke) (Group
et al., 1997)
ACE  inhibitors Angiotensin II inhibitors Oxidative stress, mitochondria
survival (Benigni et al., 2009)
Yes in
Agtr1a-/- (Benigni
et al., 2009);
polymorphism
associated with
longevity in
humans (Benigni
et al., 2013)
Decreased cardiac vascular
injury (Benigni et al., 2009)
High blood
pressure
Quercetin Inhibit PI3 K, mTOR, serpines
(Bruning, 2013)
Eliminate senescent cells (Zhu
et al., 2015)
N/A Given in combination with
Quercetin Improved CVD,
mobility
Osteoporosis, frailty (Zhu et al.,
2015)
Approved for
human use but
little evidence of
efﬁcacy in any
application
Dasatinib Tyrosine kinase inhibitor
(Montero et al., 2011)
Induce apoptosis(Bannister
et al., 2014), eliminate
senescence cells (Zhu et al.,
2015)
N/A Given in combination with
quercetin, improved CVD,
mobility
Osteoporosis, frailty (Zhu et al.,
2015)
Cancer treatment
(Talpaz et al., 2006)
ABT263  BCL-2 and BCL-xL inhibitor
(Tse et al., 2008)
Induce apoptosis (Tse et al.,
2008), eliminate senescent
cells (Chang et al., 2016)
N/A Recover ﬁtness of
hematopoietic and muscle
stem cells (Chang et al., 2016)
Cancer treatment
(Gandhi et al.,
2011)
Zoledronate FPP synthase inhibitor Enhance DNA damage repair
(Misra et al., 2016)
Yes in combination
with statin in HGPS
(Varela et al., 2008)
&  patients with
osteoporosis
(Colón-Emeric
et al., 2010)
N/A Osteoporosis,
cancer bone loss
(Russell, 2011)
Methylene Blue Increases activity of
mitochondria complex IV
(Atamna et al., 2008)
Senescence, mitochondrial
activity (Atamna et al., 2008),
oxidative stress
Yes, maximal
lifespan in female
(Harrison et al.,
2014)
Neurodegenerative diseases
(AD, PD) (Yang et al., 2015)
Ifosfamide induced
encephalopathy
(Pelgrims et al.,
1999)
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Table  2 (Continued)
Molecule Target Modiﬁed ageing mechanisms Lifespan extension Healthspan with age/disease
improvement
Human testing
PAI-1 Inhibitors Inhibitors of plasminogen
activator inhibitor-1 (PAI-1)
Induce ﬁbrinolysis, delay
senescence (Eren et al., 2014)
Yes in klotho-/-
mice (Eren et al.,
2014)
Improves renal, lung structure
in klotho-/- mice (Eren et al.,
2014), reduce hypertension,
vascular senescence (Boe et al.,
2013), thrombotic disorders
(Hennan et al., 2005)
Molecules have
been patented but
none has been
trialled in humans
(Fortenberry, 2013)
Mitochondria
targeted
anti-oxidant
peptides (MitoQ
and SS-31)
Increase mitochondrial
biogenesis, anti-oxidant (Kelso
et  al., 2001)
Oxidative stress (Kelso et al.,
2001)
Yes in C. elegans
(MitoQ) (Ng et al.,
2014)
Reduce AD progression
(McManus et al., 2011), PD
(Yang et al., 2009), Improve
muscle weakness (Siegel et al.,
2013) CVD (Dai et al., 2014),
diabetes (Anderson et al., 2009)
SS-31 Ischemia
reperfusion injury
(Chakrabarti et al.,
2013), MitoQ
clinical trial in PD
(Snow et al., 2010)
and liver damage
(Gane et al., 2010)
Minocycline Broad spectrum Tetracycline
antibiotic, inhibits Kynurenine
formation from Tryptophan
Inhibit inﬂammation (Kelly
et al., 2004), oxidative stress
(Kraus et al., 2005; Morimoto
et al., 2005)
Yes in Drosophila
(Oxenkrug et al.,
2012), C. elegans
(Ye et al., 2014)
Attenuates neurodenegerative
disease (Blum et al., 2004)
Acne vulgaris
(Strauss et al.,
2007)
JAK  inhibitors JAK1 and JAK2 Inhibition of SASP (Xu et al.,
2015)
N/A Improve muscle weakness (Xu
et al., 2015)
Myeloﬁbrosis
(Harrison et al.,
2012; Pardanani
et al., 2013; O’Shea
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in preclinical studies using multiple models, exposed to clinically
relevant stresses according to standardised methodologies withal vs cross-sectional), group size, gender (male versus female),
enetic background of the mice, route of delivery and treatment
uration. In this respect prolonged rapamycin treatment resulted
n improved metabolic proﬁles, increased oxygen consumption and
etogenesis and markedly enhancing insulin sensitivity (Fang et al.,
013). In contrast, mice exposed to a more acute rapamycin treat-
ent showed impaired glucose tolerance (Lamming et al., 2012).
ore importantly signs of nephro- and gonadotoxicity have been
ound following prolonged rapamycin treatment (Neff et al., 2013)
utting into question whether rapamycin’s beneﬁcial effects can
e translated to humans. One major caveat to all the studies is the
se of a single dose of rapamycin and a single regime. Different
ystems may  be sensitive to different doses or length of time of
reatment. More work is required to identify the correct dose, time
nd length of administration so that this is suitable to correct the
any signs of ageing and reduce the side effects (Kaeberlein, 2014).
igniﬁcant research effort is currently being undertaken to identify
afer drugs, termed rapalogs, which can provide all the beneﬁts
f rapamycin on lifespan and healthspan without the unwanted
ide-effects (Lamming et al., 2013).
More recently metformin has taken central stage. It is a clinically
pproved drug commonly prescribed as an anti-hyperglycaemic
gent in the treatment of type 2 diabetes (Campbell et al.,
996). Long-term treatment with low-dose metformin starting
n middle age has been shown to promote healthy ageing and
ongevity in male mice by 4–6%, although a higher dose shortens
ongevity (Martin-Montalvo et al., 2013). A similar small but signif-
cant increase in survival was observed in patients with diabetes
reated with metformin compared to patients without diabetes
Bannister et al., 2014). Metformin has also been shown to improve
lobal metabolic ﬁtness similarly to dietary restriction in aged
ice, resulting in improved endurance, insulin sensitivity, reduced
xidative damage and chronic inﬂammation, reducing tumorigen-
sis (Martin-Montalvo et al., 2013; Anisimov, 2015) and this was
irrored by a decreased cancer risk in patients with diabetes (Noto
t al., 2012). In addition a recent study linked this antineoplastic
ctivity of metformin to inhibition of the SASP by interfering with
roinﬂammatory NF-B signalling (Moiseeva et al., 2013). These
vidences led to the FDA approval of a clinical trial to investigate the
ction of metformin on human ageing in the Targeting/Taming Age-et al., 2015;
Verstovsek et al.,
2012)
ing With Metformin (TAME) study. This is to generate data as proof
of principle that the ageing process can be viewed as an indication
for pharmacological intervention. Metformin success will be judged
by whether it can delay the development of several diseases whose
incidence increases dramatically with age: cardiovascular disease,
cancer, and cognitive decline, along with mortality. Whilst a success
will fast forward research into such interventions, there are con-
cerns that it is too early for such a large trial and more work should
be performed to thoroughly assess the effects of these molecules on
multiple systems, their reproducibility and their safety proﬁle for
prolonged doses in healthy individuals in a heterogeneous popula-
tion as this is largely unknown. Particular consideration should be
given to the age-group and some of the problems related to drug
dosing and pharmacokinetics. For example metformin is renally
excreted and renal impairment is more common in the elderly. In
addition such trials are very expensive and cannot represent the
way these drugs will be tested. More work needs to be performed
to identify clinical situations and biomarkers that allow testing
over a shorter period of time and design of preclinical intervention
programmes that are standardised and reﬂect clinical endpoints.
6. Conclusions
The ultimate goal of geroscience, the ﬁeld that investigate the
relationship between ageing and age-related disorders, is to devise
intervention strategies to prolong health span rather than treating
individual diseases. Whilst proof-of-concept studies are available in
support of such a strategy, there are great challenges ahead. A more
systematic investigation of the mechanisms of ageing leading to
multiple diseases is required to understand the key nodes to target
for intervention and to identify biomarkers for both stratiﬁcation
of patients requiring interventions and monitoring of their efﬁ-
cacy. Pharmacological interventions need to be thoroughly testedendpoints that are clinically meaningful. Large infrastructures are
required to support the size of the studies that will involve multiple
dosing, regimens, models and interdisciplinary expertise.
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